The global epigenetics market size is projected to reach USD 4.3 billion by 2028 from USD 1.8 billion in 2023, at a CAGR of 18.3% during the forecast period. Factors such as increased investments in research and development, coupled with a reduction in sequencing costs and time, support from government initiatives and funding for epigenetics research, advancements in technology for epigenetic research, and a growing interest in epigenetic-based therapeutics. “The kits & reagents segment segment held the dominant share in the epigenetics market” Based on product & service, the global epigenetics market is segmented into kits & reagents, enzymes, instruments and accessories, software, and service. The kits & reagents segment is anticipated to grow at significant CAGR. The rapid expansion of epigenetics studies, combined with the introduction of cost-effective and user-friendly kits by market participants are likely to have positive impact on the growth of the market. “DNA methylation segment accounted for the largest share of the method segment in 2022.” Based on method, the epigenetics market is segmented into, DNA methylation, histone modifications, and other methods. In 2022, the DNA methylation segment accounted for the largest share of the epigenetics market. The segment held the dominant share in the market owing to the effectiveness of employing DNA methylation techniques for cancer research. “Asia Pacific region is likely to grow at a faster pace in the epigenetics market.” The epigenetics market region is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and the Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The growth of the region is majorly driven by enhancements in healthcare infrastructure within developing APAC economies, coupled with strategic partnerships, collaborations, agreements, and expansions pursued by local industry players. The primary interviews conducted for this report can be categorized as follows: • By Respondent: Supply Side- 60%, and Demand Side - 40% • By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25% • By Region: North America: 40%, Europe: 27%, Asia Pacific: 20%, Latin America: 10%, and the Middle East & Africa: 3% List of Companies Profiled in the Report: • Thermo Fisher Scientific Inc. (US) • Merck KGaA (Germany) • Illumina, Inc. (US) • PacBio (US) • Abcam plc (UK) • Active Motif, Inc. (US) • Bio-Rad Laboratories Inc. (US) • Promega Corporation (US) • Revvity (US) • Qiagen (Germany) • New England Biolabs (US) • Zymo Research Corporation (US) • Diagenode SA(US) • F. Hoffmann-La Roche Ltd (Switzerland) • EpiGentek Group Inc. (US) • EpiCypher (US) • Fios Genomics (UK) • GenomeScan (Netherlands) • Creative Biogene (US) • BPS Bioscienc Inc (US) • Abnova Corporation (Taiwan) • Creative Diagnostics (US) • Biomodal (UK) • Integrated DNA Technologies Inc. (US) • Novogene Co Ltd (China) Research Coverage: This report provides a detailed picture of the epigenetics market. It aims at estimating the size and future growth potential of the market across different segments such as the technology, type, disease indication, route of administration, end-user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies. Key Benefits of Buying the Report: The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall epigenetics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges. The report provides insights on the following pointers: • Analysis of key drivers (growing investment in research & development, declining sequencing cost & time, favorable government initiatives and funding for epigenetics research, technological advancements in epigenetic research and rising demand for epigenetic-based therapeutics), restraints (Limited application of epigenomic data in toxicology, data privacy concern and security issues associated with management of large scale- epigenetic data ), opportunities (Expanding application of epigenetics and integration of artificial intelligence and machine learning algorithm) and challenges (Concerns Regarding the Quality of Antibodies, Challenges associated epigenetics editing, off target effect) are influencing the growth of epigenetics market. • Product Development/Innovation: Detailed insights on newly launched products of the epigenetics market. • Market Development: Comprehensive information about lucrative markets – the report analyses the epigenetics market across varied regions. • Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the epigenetics market. • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Abcam plc (UK), Active Motif, Inc. (US), Bio-Rad Laboratories Inc. (US), Promega Corporation (US), Revvity (US) and Qiagen (Germany).

1 INTRODUCTION 44 1.1 STUDY OBJECTIVES 44 1.2 MARKET DEFINITION 44 1.2.1 INCLUSIONS & EXCLUSIONS 45 1.3 MARKET SCOPE 45 1.3.1 MARKETS COVERED 45 1.3.2 YEARS CONSIDERED 46 1.3.3 CURRENCY CONSIDERED 46 1.4 RESEARCH LIMITATIONS 46 1.5 STAKEHOLDERS 47 1.6 SUMMARY OF CHANGES 47 1.7 RECESSION IMPACT 48 2 RESEARCH METHODOLOGY 49 2.1 RESEARCH DATA 49 2.1.1 SECONDARY DATA 50 2.1.2 PRIMARY DATA 51 2.2 MARKET SIZE ESTIMATION 52 2.2.1 PRIMARY INSIGHTS 54 2.2.2 SEGMENTAL ASSESSMENT: EPIGENETICS MARKET 55 2.3 GROWTH RATE ASSUMPTIONS 56 2.4 MARKET BREAKDOWN & DATA TRIANGULATION 58 2.5 STUDY ASSUMPTIONS 59 2.6 RISK ANALYSIS 59 2.7 RECESSION IMPACT: EPIGENETICS MARKET 59 3 EXECUTIVE SUMMARY 61 4 PREMIUM INSIGHTS 65 4.1 EPIGENETICS MARKET OVERVIEW 65 4.2 NORTH AMERICA: EPIGENETICS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2022) 66 4.3 EPIGENETICS MARKET SHARE, BY PRODUCT & SERVICE, 2023 VS. 2028 67 4.4 EPIGENETICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 67 5 MARKET OVERVIEW 68 5.1 INTRODUCTION 68 5.2 MARKET DYNAMICS 68 5.2.1 DRIVERS 69 5.2.1.1 Growing investments in research & development 69 5.2.1.2 Declining sequencing costs & time 70 5.2.1.3 Favorable government initiatives and funding for epigenetics research 72 5.2.1.4 Technological advancements in epigenetics research 72 5.2.1.5 Rising demand for epigenetic-based therapeutics 73 5.2.2 RESTRAINTS 74 5.2.2.1 Limited applications of epigenomic data in toxicology 74 5.2.2.2 Data privacy concerns and security issues 75 5.2.3 OPPORTUNITIES 75 5.2.3.1 Expanding applications of epigenetics 75 5.2.3.2 Integration of artificial intelligence and machine learning algorithms 76 5.2.4 CHALLENGES 76 5.2.4.1 Concerns regarding quality of antibodies 76 5.2.4.2 Challenges associated with epigenetic editing 77 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 77 5.4 PRICING ANALYSIS 78 5.4.1 AVERAGE SELLING PRICE OF PRODUCTS, BY KEY PLAYER 78 5.4.2 AVERAGE SELLING PRICE TREND 79 5.5 TECHNOLOGY ANALYSIS 79 5.6 VALUE CHAIN ANALYSIS 80 5.7 ECOSYSTEM MAP 81 5.8 REGULATORY ANALYSIS 83 5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85 5.9 PORTER’S FIVE FORCES ANALYSIS 88 5.9.1 THREAT OF NEW ENTRANTS 88 5.9.2 THREAT OF SUBSTITUTES 89 5.9.3 BARGAINING POWER OF SUPPLIERS 89 5.9.4 BARGAINING POWER OF BUYERS 89 5.9.5 INTENSITY OF COMPETITIVE RIVALRY 89 5.10 PATENT ANALYSIS 90 5.11 KEY CONFERENCES & EVENTS 91 5.12 KEY STAKEHOLDERS & BUYING CRITERIA 92 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 92 5.12.2 BUYING CRITERIA FOR EPIGENETICS 93 6 EPIGENETICS MARKET, BY PRODUCT & SERVICE 94 6.1 INTRODUCTION 95 6.2 KITS & REAGENTS 95 6.2.1 ANTIBODIES 98 6.2.1.1 Growing demand for recombinant antibodies for detection of epigenetic targets to propel growth 98 6.2.2 CHIP-SEQUENCING KITS & REAGENTS 101 6.2.2.1 Versatile applications of chromatin immunoprecipitation (ChIP) pertaining to epigenetic regulatory systems to boost demand 101 6.2.3 BISULFITE CONVERSION KITS & REAGENTS 104 6.2.3.1 Effective outcomes associated with bisulfite conversion to drive demand 104 6.2.4 WHOLE-GENOME AMPLIFICATION KITS & REAGENTS 107 6.2.4.1 Ability of whole-genome amplification to maintain relative proportions of genes in original pool to drive adoption 107 6.2.5 5-HMC & 5-MC ANALYSIS KITS & REAGENTS 110 6.2.5.1 Introduction of unique kits for 5-mC and 5-hmC analysis to support growth 110 6.2.6 HISTONES 113 6.2.6.1 Emerging importance of chromatin-associated proteins and histones in epigenetic research to drive segmental growth 113 6.2.7 OTHER KITS & REAGENTS 116 6.3 ENZYMES 119 6.3.1 DNA-MODIFYING ENZYMES 121 6.3.1.1 Broadening applications of DNA methylation to favor market growth 121 6.3.2 PROTEIN-MODIFYING ENZYMES 124 6.3.2.1 Increasing pipeline of epigenetics-based drugs targeting histone-modifying enzymes to drive segmental growth 124 6.3.3 OTHER ENZYMES 127 6.4 INSTRUMENTS & ACCESSORIES 129 6.4.1 WIDE USAGE OF NGS INSTRUMENTS AND SONICATORS TO PROPEL GROWTH 129 6.5 SOFTWARE 132 6.5.1 DEVELOPMENT OF VIABLE SOFTWARE SOLUTIONS FOR DNA METHYLATION AND RNA ANALYSIS TO PROPEL GROWTH 132 6.6 SERVICES 135 6.6.1 EXPANDING POOL OF SERVICE PROVIDERS TO DRIVE GROWTH 135 7 EPIGENETICS MARKET, BY METHOD 139 7.1 INTRODUCTION 140 7.2 DNA METHYLATION 140 7.2.1 INCREASING R&D ACTIVITIES TO EXPLORE POTENTIAL OF DNA METHYLATION TO DRIVE MARKET GROWTH 140 7.3 HISTONE MODIFICATIONS 143 7.3.1 TECHNOLOGICAL ADVANCEMENTS TO DRIVE SEGMENTAL GROWTH 143 7.4 OTHER METHODS 146 8 EPIGENETICS MARKET, BY TECHNIQUE 150 8.1 INTRODUCTION 151 8.2 NGS 151 8.2.1 ABILITY TO OFFER COMPREHENSIVE EPIGENETIC PROFILES TO PROPEL DEMAND FOR NGS TECHNIQUE 151 8.3 PCR & QPCR 154 8.3.1 RISING NUMBER OF PCR-BASED EPIGENETICS SERVICE PROVIDERS TO DRIVE GROWTH 154 8.4 MASS SPECTROMETRY 157 8.4.1 GROWING DEMAND FOR MASS SPECTROMETRY IN COMPREHENSIVE STUDIES ON HISTONE EPIGENETICS TO BOOST MARKET 157 8.5 SONICATION 160 8.5.1 INTRODUCTION OF IMPROVED HIGH-THROUGHPUT SONICATION TECHNIQUES TO PROPEL ADOPTION 160 8.6 OTHER TECHNIQUES 163 9 EPIGENETICS MARKET, BY APPLICATION 167 9.1 INTRODUCTION 168 9.2 ONCOLOGY 168 9.2.1 GROWING EFFORTS TO DEVELOP ONCOLOGY EPIGENETIC DRUGS TO BOOST MARKET 168 9.3 METABOLIC DISEASES 173 9.3.1 EMERGING ROLE OF DNA METHYLATION IN DIABETES MANAGEMENT TO FAVOR MARKET GROWTH 173 9.4 IMMUNOLOGY 176 9.4.1 GROWING DEMAND FOR EPIGENETIC PRODUCTS IN TUMOR AND TRANSPLANTATION IMMUNOLOGY TO SUPPORT GROWTH 176 9.5 DEVELOPMENTAL BIOLOGY 179 9.5.1 INCREASING RESEARCH IN DEVELOPMENTAL BIOLOGY TO PROPEL GROWTH 179 9.6 CARDIOVASCULAR DISEASES 182 9.6.1 EMERGING ROLE OF EPIGENETICS IN UNDERSTANDING ETIOLOGY OF CARDIOVASCULAR DISEASES TO BOOST ADOPTION 182 9.7 OTHER APPLICATIONS 185 10 EPIGENETICS MARKET, BY END USER 189 10.1 INTRODUCTION 190 10.2 ACADEMIC & RESEARCH INSTITUTES 190 10.2.1 INCREASING GOVERNMENT INVESTMENTS & COLLABORATIONS TO CONTRIBUTE TO MARKET GROWTH 190 10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 193 10.3.1 GROWING NUMBER OF CLINICAL TRIALS FOR EPIGENETICS-BASED DRUGS TO DRIVE GROWTH 193 10.4 HOSPITALS & CLINICS 196 10.4.1 GROWING IMPORTANCE OF MEASUREMENT OF DNA METHYLATION IN HOSPITAL SETTINGS TO BOOST MARKET 196 11 EPIGENETICS MARKET, BY REGION 200 11.1 INTRODUCTION 201 11.2 NORTH AMERICA 201 11.2.1 US 205 11.2.1.1 Strong network of well-established epigenetic product manufacturers to drive market growth 205 11.2.2 CANADA 209 11.2.2.1 Increasing government initiatives to boost epigenetics research 209 11.3 NORTH AMERICA: RECESSION IMPACT 213 11.4 EUROPE 214 11.4.1 GERMANY 217 11.4.1.1 Significant investments in NGS to boost adoption of epigenetics products 217 11.4.2 UK 221 11.4.2.1 Rising acceptance of genome-based diagnostic techniques by clinicians to support growth 221 11.4.3 FRANCE 224 11.4.3.1 Growing demand for PCR technologies to propel market growth 224 11.4.4 ITALY 227 11.4.4.1 High incidence of cancer to support market growth 227 11.4.5 SPAIN 230 11.4.5.1 Well-established network of research centers and universities to boost market 230 11.4.6 REST OF EUROPE 233 11.5 EUROPE: RECESSION IMPACT 236 11.6 ASIA PACIFIC 237 11.6.1 JAPAN 242 11.6.1.1 Increasing collaborations between research & academic organizations to favor market growth 242 11.6.2 CHINA 246 11.6.2.1 High demand for personalized medicine to fuel growth 246 11.6.3 INDIA 250 11.6.3.1 Expanding base of biotechnology facilities to drive growth 250 11.6.4 SOUTH KOREA 254 11.6.4.1 Increasing demand for epigenetic testing to boost growth 254 11.6.5 REST OF ASIA PACIFIC 257 11.6.6 ASIA PACIFIC: RECESSION IMPACT 260 11.7 LATIN AMERICA 261 11.7.1 BRAZIL 264 11.7.1.1 Increasing number of healthcare providers incorporating epigenetic testing to boost growth 264 11.7.2 MEXICO 267 11.7.2.1 Growing adoption of cutting-edge technologies to support growth 267 11.7.3 REST OF LATIN AMERICA 270 11.7.4 LATIN AMERICA: RECESSION IMPACT 273 11.8 MIDDLE EAST 274 11.8.1 INCREASE IN FUNDING AND PARTNERSHIPS IN RESEARCH SECTOR TO BOOST GROWTH 274 11.8.2 MIDDLE EAST: RECESSION IMPACT 277 11.9 AFRICA 278 11.9.1 GROWING COLLABORATIONS TO SUPPORT GROWTH IN COMING YEARS 278 11.9.2 AFRICA: RECESSION IMPACT 281 12 COMPETITIVE LANDSCAPE 282 12.1 INTRODUCTION 282 12.2 STRATEGIES ADOPTED BY KEY PLAYERS 283 12.3 REVENUE ANALYSIS 284 12.4 MARKET SHARE ANALYSIS 284 12.5 COMPANY EVALUATION MATRIX 286 12.5.1 STARS 286 12.5.2 EMERGING LEADERS 287 12.5.3 PERVASIVE PLAYERS 287 12.5.4 PARTICIPANTS 287 12.5.5 COMPANY FOOTPRINT ANALYSIS 289 12.6 START-UP/SME EVALUATION QUADRANT 291 12.6.1 PROGRESSIVE COMPANIES 291 12.6.2 RESPONSIVE COMPANIES 291 12.6.3 DYNAMIC COMPANIES 291 12.6.4 STARTING BLOCKS 291 12.6.5 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 293 12.7 COMPETITIVE SCENARIO & TRENDS 294 12.7.1 PRODUCT LAUNCHES & APPROVALS 294 12.7.2 DEALS 295 12.7.3 OTHER DEVELOPMENTS 296 13 COMPANY PROFILES 297 13.1 KEY MARKET PLAYERS 297 13.1.1 THERMO FISHER SCIENTIFIC INC 297 13.1.2 ILLUMINA, INC 301 13.1.3 MERCK KGAA 305 13.1.4 PACBIO 309 13.1.5 ABCAM PLC 313 13.1.6 BIO-RAD LABORATORIES, INC 317 13.1.7 ACTIVE MOTIF INC 322 13.1.8 NEW ENGLAND BIOLABS 326 13.1.9 QIAGEN 329 13.1.10 ZYMO RESEARCH CORPORATION 332 13.1.11 REVVITY 335 13.1.12 DIAGENODE SA (A HOLOGIC COMPANY) 338 13.1.13 F. HOFFMANN-LA ROCHE LTD 341 13.1.14 PROMEGA CORPORATION 343 13.1.15 EPIGENTEK GROUP INC 345 13.2 OTHER PLAYERS 349 13.2.1 EPICYPHER 349 13.2.2 FIOS GENOMICS 350 13.2.3 GENOMESCAN 351 13.2.4 CREATIVE BIOGENE 352 13.2.5 BPS BIOSCIENCE, INC 353 13.2.6 ABNOVA CORPORATION 354 13.2.7 CREATIVE DIAGNOSTICS 355 13.2.8 BIOMODAL (FORMERLY CAMBRIDGE EPIGENETIX) 356 13.2.9 INTEGRATED DNA TECHNOLOGIES, INC 356 13.2.10 NOVOGENE CO., LTD 358 14 APPENDIX 359 14.1 DISCUSSION GUIDE 359 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 363 14.3 CUSTOMIZATION OPTIONS 365 14.4 RELATED REPORTS 365 14.5 AUTHOR DETAILS 366